Genetically, lesion-confined mTOR-pathway mosaicism accounts for a substantial subset of FCD type II, while SLC35A2 mutations underlie mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). Here, SLC35A2 is linked to epilepsy.